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in 10,000 inhabitants. Although individually rare, together, rare diseases affect 
significant part of the population. Therefore, patient access to orphan medicines 
is receiving increasing political attention in the EU. The objective of our study 
was to determine the access to orphan medicines in Serbia. METHODS: Serbian 
Reimbursement List has been reviewed and identified orphan medicines were 
crossed with the List of orphan drugs in Europe, published in July 2011, available 
from Orphanet. The analysis of regulatory traits was based on a review of official 
documents setting out legislation regarding rare diseases and orphan medicines 
in Serbia. RESULTS: Only 6.5% (4 out of 61) of authorised orphan medicines in 
Europe with prior orphan designation and 25.0% (17 out of 68) without prior 
orphan designation were available and reimbursed in Serbia. According to the 
first level of the ATC Classification System, most of reimbursed orphan 
medicines belonged to the group L – ‘Antineoplastic and immunomodulating 
agents’. It is estimated that there are approximately 500,000 patients suffering 
from rare diseases in Serbia. Although the National register for rare diseases 
does not exist, the Law on Health Care provides for the forming of the official 
centres of reference for rare diseases that have the obligation of diagnosing, 
treatment and patient counseling, but also of creation of National register. 
Neither policy measures nor research incentives for rare diseases exist in Serbia. 
CONCLUSIONS: The low share of reimbursed orphan drugs in Serbia may be due 
to incomplete compliance with legislation of EU and existence of domestic 
procedure for authorisation. The EU policy on treatment of rare diseases 
facilitate the penetration of orphan drugs on the EU market, but apparently there 
is also considerable budget impact on the availability of orphan medicines.  
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OBJECTIVES: The United States (US) and the European Union (EU) implemented 
regulations for encouraging the development of drugs for rare diseases. Criteria 
for Orphan designation is generally based on the number of patients affected by 
the disease (<200,000 US patients and <5 in 10,000 EU patients). The EU also 
requires that a satisfactory alternative treatment is not available or that the new 
drug is significantly better than drugs currently marketed. We examined the 
characteristics of orphan drug (OD) designations and approvals by the US Food 
and Drug Administration (FDA) and the European Medicines Agency (EMA) 
between 2000 and 2011. METHODS: Data for orphan designations and approvals 
were extracted from the FDA and EMA online databases for the period 2000-2011. 
Data were updated to September 14, 2012. The time for OD designation to 
approval was estimated. Descriptive analysis, chi-square test, and group 
comparison t-tests were used in the analysis. RESULTS: The FDA granted 1558 
orphan designations for 1133 different products, and 149 approvals (9.6% of 
designated products), and the EMA 935 designations for 639 different products 
and 88 (9.4%) approvals during the study period. The time from OD designation 
to approval was 2.74±2.39 years in the FDA and 3.31±1.99 years in EME (p<0.05). 
EMA approved a larger number of designations (15.2%) than the FDA (12.3%) for 
the 569 products designated by both agencies; 67% of these products were first 
designated by the FDA and 78% of the 50 products approved by both agencies 
were approved first by EMA (p<0.001). CONCLUSIONS: The EU had more 
restrictive criteria for orphan designation and significantly longer approval 
times, less orphan designations, and fewer product approvals than the US. 
Harmonization of the Orphan drug regulatory processes of FDA and EME could 
result in improved access to ODs in the US and the EU.  
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OBJECTIVES: Opioid abuse is a significant public health problem in the United 
States, with opioid-related overdoses accounting for over 16,500 deaths per year. 
In addition, opioid abuse imposes a significant economic burden due to 
increased health care utilization and costs. This study calculates updated, payer-
specific, excess medical costs of diagnosed opioid abuse among commercially-
insured, Medicaid, and Medicare patients with recent prescription opioid (RxO) 
use. METHODS: Using de-identified Truven MarketScan medical and pharmacy 
claims data for commercially-insured, Medicaid, and Medicare patients, we 
examined the excess costs of diagnosed opioid abuse among patients with at 
least one pharmacy claim for an RxO, 2009-2011. Diagnosed abusers were 
identified using ICD-9 diagnosis codes for opioid abuse/dependence and were 
matched to non-abusers using propensity score methods. Medical costs were 
calculated over a 12-month period around the index date, which was the date of 
the first abuse diagnosis for abusers and the date of a random medical claim for 
non-abusers. Costs reflected payments by insurers as well as out-of-pocket 
patient costs, measured in 2011USD. The excess costs of diagnosed opioid abuse 
were calculated as the difference in costs between abusers and non-abusers 
following matching and included inpatient, emergency room (ER), and outpatient 
services. RESULTS: A total of 2510 commercially-insured, 536 Medicaid, and 268 
Medicare patients with diagnosed opioid abuse were matched to non-abusers. 
The annual per patient excess medical costs associated with diagnosed opioid 
abuse were $9,456 (p<0.001) for commercially-insured patients, $11,501 (p<0.001) 
for Medicaid patients, and $10,046 (p<0.001) for Medicare patients. Inpatient 
costs accounted for 63.0%-78.6% of total excess medical costs, and ER costs 
accounted for 5.6%-12.6% of total excess medical costs. CONCLUSIONS: The 
excess medical costs of opioid abuse are substantial and reveal a consistent 
pattern across payers. These estimates are comparable to prior research, 
suggesting opioid abuse continues to impose significant economic burden.  
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OBJECTIVES: Opioids, generally recommended as second- or third-line agents for 
neuropathic pain (NeP), are commonly used. This study characterized opioid and 
antiepileptic drug (AED) utilization among patients with NeP associated with 
diabetic peripheral neuropathy (DPN), HIV, spinal cord injury (SCI), chronic low-
back pain (CLBP), post-trauma/post-surgery (PTPS), and small-fiber involvement 
(SF) stratified by pain severity (mild, moderate, severe). METHODS: Data were 
from an observational study of NeP patients recruited during routine visits with 
primary-care or specialty physicians. Subjects completed a one-time 
questionnaire, and investigators completed a case report form based on a 6-
month retrospective chart review. Pain severity was based on the Brief Pain 
Inventory average pain score. RESULTS: A total of 624 subjects were enrolled: 
71.8% were white; 55.4% were male; mean age was 55.5±13.7 years; with a mean 
of 7.8±6.8 years since NeP diagnosis. The proportion of patients with each NeP 
indication was similar (16.0%-17.9%). Pain severity was mild, moderate, and 
severe in 17.6%, 47.6%, and 33.2%, respectively. The most frequently used NeP 
medications over the past 6 months were opioids (53.0%) and AEDs (49.0%), 
ranging from 33.0% (DPN) to 81.1% (CLBP) for opioids, and 28.3% (CLBP) to 64.1% 
(SCI) for AEDs. Overall, AED use remained unchanged across pain severity 
categories (46.4%-50.5%), while opioid use increased significantly with greater 
pain severity: 28.2% mild, 53.2% moderate, 65.2% severe (p<0.0001). Opioids were 
used by substantial proportions of patients across all pain severity levels 
including 33.3% in SCI, 50.0% in CLBP, and 71.4% in PTPS. Except for DPN, strong 
short-acting opioids were the most frequently used opioid class, ranging from 
14.3% in DPN to 55.7% in CLBP. CONCLUSIONS: Patterns of opioid use observed in 
this study were not fully consistent with published guidelines; opioid use was 
common across six different chronic NeP conditions and did not appear to be 
reserved for more severe pain patients.  
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OBJECTIVES: Evaluation of measures of medication-taking behavior is 
uncommon with infusible pharmacologic agents. This study evaluated 
persistence and adherence measures from utilization data on the infusible anti-
inflammatory biologic infliximab. METHODS: Patients were identified through 
the electronic health records (EHR) with ICD-9 diagnoses of rheumatoid arthritis 
(714.xx), psoriatic arthritis (696.xx), ulcerative colitis (556.xx), or Crohn’s disease 
(555.xx). Incident infliximab-treated patients between January 1, 2007 and June 
30, 2011, ≥18 years of age, with ≥1 maintanence dose were included. Infliximab 
dosing data were extracted from medical chart review and the EHR. We 
employed Kaplan-Meier (KM) analyses to estimate median time to treatment 
discontinuation and Cox regression to evaluate factors associated with 
discontinuation. Medication possession ratio (MPR) was calculated as sum of 
prescribed infusion frequency intervals divided by days from first infusion to last 
infusion. Compliance was defined as MPR ≥0.80. Proportion of days covered was 
also explored (data not shown). Sensitivity analyses were performed for various 
definitions of “treatment gap” and “discontinuation”. Analyses are shown for gap 
of ≥90 days. For all test statistics, a p-value <0.05 was considered statistically 
significant. RESULTS: We identified 122 patients meeting study inclusion criteria. 
Mean age of patients was 45 years and 61% were female. KM estimated a median 
treatment duration of 23 months and adjusted Cox regression identified African 
Americans at significantly greater risk for treatment discontinuation than 
Caucasians (hazard ratio: 4.95; 95% confidence interval: 1.11, 22.05; P=0.036). A 
total of 100 patients had a calculable MPR, mean and median MPR were 0.937 and 
0.956, respectively, with 93% of patients compliant with treatment. Sensitivity 
analyses showed varied results depending on definitions. CONCLUSIONS: 
Patients receiving infliximab were overall compliant with therapy during a 
median of 23 months of treatment. Underlying definitions used with MPR and 
KM are important, and should be clinically meaningful and transparent.  
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